Neurovascular Access Catheters Market Size

Neurovascular Access Catheters Market Analysis

During the time frame of the forecast, the neurovascular access catheters market is expected to grow at a CAGR of 4.9%.

COVID-19 had a big effect on the market for neurovascular access catheters because many neurovascular surgeries had to be put off or stopped during the first wave of the pandemic. For example, a February 2021 article in PubMed says that coronavirus affects neurological presentations and health status because neurological patients need to stay in the hospital more often and have a higher risk of death and disability when they get out.Due to the global lockdown, it was hard for patients with neurological problems to get regular checks and treatment, which had a big effect on the market studied.But now that the restrictions have been lifted, the market is likely to grow because neurovascular problems are becoming more common and more people are using neurovascular access catheters.

Market growth is likely to be driven by things like the rise of neurovascular diseases and the improvement of neurovascular catheter technology.For example, according to an article in Frontiers from March 2022, the estimated global incidence of subarachnoid hemorrhage (SAH) is 6.67 per 100,000 people. Each year, SAH affects nearly 500,000 people, and nearly two-thirds of these people live in low- and middle-income countries.Furthermore, technological advances in neurovascular access catheters are expected to drive market growth over the forecast period. For instance, in February 2022, CERENOVUS, an emerging company that focuses on neurovascular care and is part of the Johnson & Johnson Medical Device Companies, launched the EMBOGUARD, a next-generation balloon guide catheter to be used in endovascular procedures, including those for patients with acute ischemic stroke.

Also, research studies and comparisons of the different neurovascular access catheters should help the market grow during the study period. For example, a September 2022 article in PubMed said that a 0.096-inch inner diameter access catheter could be used for neurovascular treatments through both the femoral artery and the radial artery. It had a good rate of technical success and a low rate of problems during the procedure.

So, the studied market is likely to grow over the next few years because neurovascular complications are getting worse, more neurovascular access catheter products are coming out, and more research and development is being done. But problems with biocompatibility are likely to slow market growth for neurovascular access catheters.